University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine

    Thumbnail
    Citations
    Altmetric
    Author
    Litt, J; Booy, R; Bourke, D; Dwyer, DE; Leeb, A; McCloud, P; Stein, AN; Woodward, M; Cunningham, AL
    Date
    2020-05-18
    Source Title
    Human Vaccines and Immunotherapeutics
    Publisher
    TAYLOR & FRANCIS INC
    University of Melbourne Author/s
    Woodward, Michael
    Affiliation
    Medicine and Radiology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Litt, J., Booy, R., Bourke, D., Dwyer, D. E., Leeb, A., McCloud, P., Stein, A. N., Woodward, M. & Cunningham, A. L. (2020). Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 16 (12), https://doi.org/10.1080/21645515.2020.1754702.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254206
    DOI
    10.1080/21645515.2020.1754702
    Open Access URL
    http://doi.org/10.1080/21645515.2020.1754702
    Abstract
    Herpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination for eligible adults aged 70 years, with a 5-year catch-up program (until October 2021) for adults aged 71-79 years. Patterns and impact of the program were evaluated by analysis of vaccine distribution and delivery data and specific antiviral prescription data from the Pharmaceutical Benefits Scheme. During the first 2 years, uptake of funded live attenuated shingles vaccine ZOSTAVAX® (Zoster Virus Vaccine Live; ZVL) was high across the ongoing and catch-up programs. Before program implementation (2006-2016), herpes zoster coded antiviral prescription rates increased by 2.2% per year (95% CI: 1.5, 2.9) in the 70-79 years age group. In the two years since program launch, herpes zoster antiviral prescription rates declined substantially in this age group, by an average of 13.6% per year (95% CI: 1.5, 24.2). These results indicate that the National Shingles Vaccination Program has been highly successful in vaccinating a considerable proportion of Australian adults aged 70-79 years against herpes zoster and suggest that vaccine uptake was associated with decreased incidence of herpes zoster.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45770]
    • Medicine and Radiology - Research Publications [2347]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors